The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.


BACKGROUND:Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is used as monotherapy for chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type (WT) KRAS tumors. Although skin toxicities are the most common adverse events associated with EGFR inhibitors, the differences in efficacy and safety between pre-emptive and reactive skin treatment according to KRAS tumor status has not been reported. PATIENTS AND METHODS:Eligible patients had mCRC with disease progression or unacceptable toxicity with first-line treatment containing fluoropyrimidine and oxaliplatin-based chemotherapy ± bevacizumab. Patients were randomized 1:1 to pre-emptive or reactive skin treatment (after skin toxicity developed). Patients received either panitumumab 6 mg/kg + FOLFIRI every 2 weeks or panitumumab 9 mg/kg + irinotecan every 3 weeks. Key study endpoints included overall response rate (ORR), overall survival, progression-free survival (PFS), and safety according to KRAS tumor status. RESULTS:Eighty-seven (92%) of 95 enrolled patients had evaluable KRAS tumor status: 49 (56%) patients with WT and 38 (44%) patients with mutant (MT) KRAS tumors, respectively. The ORR was 16% and 8% for patients with WT and MT KRAS tumors, respectively. Median PFS was 5.5 and 3.3 months for patients with WT and MT KRAS tumors, respectively. The most commonly observed adverse events by KRAS tumor status included dermatitis acneiform and pruritus. CONCLUSION:Panitumumab in combination with irinotecan-based chemotherapy has an acceptable toxicity profile in second-line therapy for mCRC. Numerical differences trending in favor of the patients with WT KRAS tumors were observed for most efficacy endpoints.


Clin Colorectal Cancer


Mitchell EP,Piperdi B,Lacouture ME,Shearer H,Iannotti N,Pillai MV,Xu F,Yassine M




Has Abstract


2011-12-01 00:00:00














  • Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer.

    abstract:BACKGROUND:With improved survival and longer duration of treatment, clinicians managing metastatic colorectal cancer (mCRC) increasingly consider intermittent (IC) or maintenance chemotherapy (MC), but the effect of these treatment modifications on real-world outcomes is unclear. PATIENTS AND METHODS:Using a populatio...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Loree JM,Tan SK,Lafond LM,Speers CH,Kennecke HF,Cheung WY

    更新日期:2018-03-01 00:00:00

  • Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.

    abstract:BACKGROUND:In this study, the maximum tolerated dose and toxicity profile of FOLFIRI (infusional fluorouracil [5-FU]/leucovorin/irinotecan) plus gefitinib (an oral inhibitor of the epidermal growth factor receptor) were evaluated as first-line therapy in patients with metastatic colorectal cancer. PATIENTS AND METHODS...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Wolpin BM,Clark JW,Meyerhardt JA,Earle CC,Ryan DP,Enzinger PC,Zhu AX,Blaszkowsky L,Battu S,Fuchs CS

    更新日期:2006-09-01 00:00:00

  • Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System.

    abstract:BACKGROUND:Metastatic colorectal cancer (CRC) outcomes continue to improve, but they vary significantly by race and ethnicity. We hypothesize that these disparities arise from unequal access to care. MATERIALS AND METHODS:The Harris Health System (HHS) is an integrated health delivery network that provides medical car...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Lau-Min K,Prakash P,Jo E,Thrift AP,Hilsenbeck S,Musher BL

    更新日期:2020-06-01 00:00:00

  • Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age.

    abstract:BACKGROUND:Screening protocols for colorectal cancer are broadly recommended and effective in reducing mortality. However, populations from different age groups can harbor distinct pathologic and molecular profiles that can also be influenced by screening and polyp resection, especially in older ages. PATIENTS AND MET...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Pereira AAL,Fernandes GDS,Braga GTP,Marchetti KR,Mascarenhas CDC,Gumz B,Crosara M,Dib L,Girardi D,Barrichello A,Seidler H

    更新日期:2020-12-01 00:00:00

  • Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.

    abstract::This article reviews the current status of the topoisomerase I (top I) inhibitors in the treatment of gastrointestinal (GI) malignancies. We focus on oral drug administration, the mode of administration that is generally preferred by patients with cancer. However, the great majority of the studies have been performed ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审


    authors: Kuppens IE,Beijnen J,Schellens JH

    更新日期:2004-09-01 00:00:00

  • Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value?

    abstract::As new improvements in the treatment of colorectal cancer have become available, it has become important to understand the benefits of new therapies or the deleterious effects stemming from the increased risk of toxicity. In particular, a more rational approach to adjuvant chemotherapy for patients with stage II/III d...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审


    authors: Funaioli C,Pinto C,Mutri V,Di Fabio F,Ceccarelli C,Martoni AA

    更新日期:2006-05-01 00:00:00

  • Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.

    abstract:BACKGROUND:The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation (ICECREAM) study assessed the efficacy of cetuximab monotherapy compared with cetuximab combined with chemotherapy for quadruple wild-type (KRAS, NRAS, BRAF, or P13KCA exon 20) metastatic colorectal cancer. PATIENTS AND METHODS:Patients w...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,多中心研究,随机对照试验


    authors: Shapiro JD,Thavaneswaran S,Underhill CR,Robledo KP,Karapetis CS,Day FL,Nott LM,Jefford M,Chantrill LA,Pavlakis N,Tebbutt NC,Price TJ,Khasraw M,Van Hazel GA,Waring PM,Tejpar S,Simes J,Gebski VJ,Desai J,Segelov E

    更新日期:2018-12-01 00:00:00

  • Positron emission tomography for the evaluation of patients with colorectal cancer.

    abstract::Approximately 40% of patients treated with curative intent for colorectal carcinoma eventually recur. In about one third of these patients, the lesion is localized and potentially resectable. Typically, the recurrence is characterized by findings on diagnostic imaging studies and may be accompanied by a rise in the se...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Fogarasi MC,Zelkowitz RS,Messana SA,Arrighi JA,Seibyl JP,Kummar S

    更新日期:2001-08-01 00:00:00

  • Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy.

    abstract:INTRODUCTION:Patients with metastatic colorectal cancer (CRC) may present with oligometastatic lung lesions for which stereotactic ablative radiotherapy (SABR) can be utilized. This study aims to report efficacy and prognostic factors associated with colorectal lung metastases treated with SABR. MATERIAL AND METHODS:T...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Kinj R,Bondiau PY,François E,Gérard JP,Naghavi AO,Leysalle A,Chamorey E,Evesque L,Padovani B,Ianessi A,Benezery K,Doyen J

    更新日期:2017-09-01 00:00:00

  • A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer.

    abstract:INTRODUCTION:The aim of this study was to evaluate the efficacy and safety of maintenance therapy with axitinib versus placebo following induction therapy in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS:In this double-blinded, phase II trial, patients with mCRC who had not progressed after 6...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,多中心研究,随机对照试验


    authors: Grávalos C,Carrato A,Tobeña M,Rodriguez-Garrote M,Soler G,Vieitez JM,Robles L,Valladares-Ayerbes M,Polo E,Limón ML,Safont MJ,Martínez de Castro E,García-Alfonso P,Aranda E,Spanish Cooperative Group for the Treatment of Digest

    更新日期:2018-06-01 00:00:00

  • Functional imaging of colorectal cancer: positron emission tomography, magnetic resonance imaging, and computed tomography.

    abstract::In the past 10 years, overall survival and disease-free survival of patients with colorectal cancer (CRC) has improved substantially because of a combination of factors: (1) more accurate staging as a result of advances in imaging technology; (2) refinements in surgical technique; (3) 'curative' metastasectomy for pat...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Kapse N,Goh V

    更新日期:2009-03-01 00:00:00

  • Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.

    abstract:INTRODUCTION:Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU. Given the additional benefit of oxaliplatin over FP alone in the management of color...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Chakrabarti S,Sara J,Lobo R,Eiring R,Finnes H,Mitchell J,Hartgers M,Okano A,Halfdanarson T,Grothey A

    更新日期:2019-03-01 00:00:00

  • Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.

    abstract:BACKGROUND:Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-r...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Sunakawa Y,Yang D,Cao S,Zhang W,Moran M,Astrow SH,Hsiang J,Stephens C,Tsuji A,Takahashi T,Tanioka H,Negoro Y,Takagane A,Tani S,Yamaguchi T,Eto T,Fujii M,Ichikawa W,Lenz HJ

    更新日期:2018-12-01 00:00:00

  • Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.

    abstract:UNLABELLED:Two identical randomized controlled trials designed to optimize adjuvant treatment of colon cancer (CC) (n =855) and rectal cancer (RC) (n = 796) were performed. Long-term evaluation confirmed that the addition of folinic acid (FA) to 5-fluorouracil (5-FU) improved 7-year overall survival (OS) in CC but not ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,随机对照试验


    authors: Kornmann M,Staib L,Wiegel T,Kron M,Henne-Bruns D,Link KH,Formentini A,Study Group Oncology of Gastrointestinal Tumors (FOGT).

    更新日期:2013-03-01 00:00:00

  • Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.

    abstract::Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal cancer of teh gastrointestinal tract. They are characterized by the expression of KIT. Therapeutically, metastatic GISTs are effectively treated by imatinib, a tyrosine kinase inhibitor (TKI) with activity against KIT and platelet-derived growth f...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审


    authors: von Mehren M

    更新日期:2006-11-01 00:00:00

  • Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases.

    abstract::The development of brain metastases originating from colorectal cancer (CRC) is an infrequent phenomenon occurring in < 5% of patients. Yet, it is feasible that physicians will be diagnosing more patients with brain metastases because of the prolonged survival in our current patient population. The anti-angiogenic age...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Bhaskara A,Eng C

    更新日期:2008-01-01 00:00:00

  • Local excision for rectal carcinoma.

    abstract::Local excision is an alternative approach to radical proctectomy for rectal cancer, but from an oncologic standpoint, it is a compromise, and its role remains controversial. Careful patient selection is essential because local excision is generally considered only for early rectal cancer with no evidence of nodal meta...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审


    authors: Kim E,Hwang JM,Garcia-Aguilar J

    更新日期:2008-11-01 00:00:00

  • Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016.

    abstract:BACKGROUND:Anal squamous cell carcinoma (ASCC) is a rare, human papilloma virus-associated cancer. The purpose was to investigate the population-based incidence rates, age and gender distribution, and survival of ASCC. MATERIALS AND METHODS:All primary ASCC in 1987 to 2016 were identified in the Cancer Registry of Nor...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Guren MG,Aagnes B,Nygård M,Dahl O,Møller B

    更新日期:2019-03-01 00:00:00

  • Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.

    abstract::Replacing infusional 5-fluorouracil (5-FU) leucovorin (LV) with oral capecitabine would be more convenient to patients, because it would lead to reduced hospital chair time and infusion-related toxicities. Previous trials with oral capecitabine-based regimens (other than XELOX [capecitabine/oxaliplatin]) have failed t...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Tyagi P,Grothey A

    更新日期:2006-11-01 00:00:00

  • Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.

    abstract::The discovery of the key role of the epidermal growth factor receptor (EGFR) and its downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has ushered in the clinical use of targeted therapies in the treatment of metastatic CRC (mCRC). The anti-EGFR monoclonal antibodies cetuximab and panitu...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审


    authors: Lee MS,Kopetz S

    更新日期:2015-12-01 00:00:00

  • Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer.

    abstract::Bevacizumab is a humanized monoclonal antibody approved by the US Food and Drug Administration for use in combination with fluorouracil (FU)-based chemotherapy for first-line treatment of patients with metastatic colorectal carcinoma (CRC). Its mechanism of action is inhibition of tumor angiogenesis by neutralizing va...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Gamboa EO,Rehmus EH,Haller N

    更新日期:2010-01-01 00:00:00

  • Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.

    abstract::Modern chemotherapy combinations for metastatic colorectal cancer (mCRC) comprise infusional 5-fluorouracil (5-FU), leucovorin, and irinotecan or oxaliplatin. The fluoropyrimidine derivative capecitabine is at least as effective as 5-FU plus leucovorin bolus regimens. It displays a favorable toxicity profile and offer...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审


    authors: Moosmann N,Heinemann V

    更新日期:2008-03-01 00:00:00

  • COVID-19 and the Global Impact on Colorectal Practice and Surgery.

    abstract:BACKGROUND:The novel severe acute respiratory syndrome coronavirus 2 virus that emerged in December 2019 causing coronavirus disease 2019 (COVID-19) has led to the sudden national reorganization of health care systems and changes in the delivery of health care globally. The purpose of our study was to use a survey to a...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Nunoo-Mensah JW,Rizk M,Caushaj PF,Giordano P,Fortunato R,Dulskas A,Bugra D,da Costa Pereira JM,Escalante R,Koda K,Samalavicius NE,Maeda K,Chun HK,ISUCRS COVID-19 Participating Investigator Group.

    更新日期:2020-09-01 00:00:00

  • Outcome of Molecular Targeted Agents Plus Chemotherapy for Second-Line Therapy of Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Trials.

    abstract:INTRODUCTION:The aim of this study was to evaluate the efficacy and toxicity of molecular targeted agents plus chemotherapy compared with chemotherapy alone as second-line therapy for patients with metastatic colorectal cancer (mCRC). MATERIALS AND METHODS:We identified randomized controlled trials that compared molec...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,meta分析


    authors: Pei X,Liu Y,Sun L,Zhang J,Fang Y,Liao X,Liu J,Zhang C,Yin T

    更新日期:2016-12-01 00:00:00

  • Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid.

    abstract:BACKGROUND:5-Fluorouracil (5-FU) chemotherapy is associated with severe and unpredictable toxicity in a significant proportion of patients. 5,10-Methylenetetrahydrofolate and 5-fluorodeoxyuridine monophosphate bind to thymidylate synthase and together inhibit its function, resulting in cytotoxicity. We hypothesized tha...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Yan M,Ho C,Winquist E,Jonker D,Rayson D,Stitt L,Tokmakejian S,Tomiak A,Vincent MD

    更新日期:2016-12-01 00:00:00

  • A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer.

    abstract::This phase II study was designed to characterize the clinical activity of ISIS 3521 in patients with metastatic colorectal cancer (CRC). Sixteen patients with pretreated or refractory CRC were treated with ISIS 3521. Eleven patients were given a dose of 2.0 mg/kg per day, and 5 patients received 3.0 mg/kg per day give...

    journal_title:Clinical colorectal cancer

    pub_type: 临床试验,杂志文章


    authors: Marshall JL,Eisenberg SG,Johnson MD,Hanfelt J,Dorr FA,El-Ashry D,Oberst M,Fuxman Y,Holmlund J,Malik S

    更新日期:2004-11-01 00:00:00

  • Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.

    abstract:BACKGROUND:Köhne prognostic score is used to classify patients with metastatic colorectal cancer (mCRC) as high, intermediate, or low risk. Using data from 2 phase III trials, we analyzed survival in patients categorized according to Köhne prognostic category and virus-induced rapidly accelerated fibrosarcoma murine sa...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Siena S,Rivera F,Taieb J,Peeters M,Prenen H,Koukakis R,Demonty G,Köhne CH

    更新日期:2018-03-01 00:00:00

  • Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.

    abstract:PURPOSE:The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those of bolus 5-fluorouracil/leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer (CRC), with favorable safety and fewer hospitalizations. Capecitabine is also at least as effective as bolus 5-FU/LV i...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Twelves CJ,Butts CA,Cassidy J,Conroy T,Braud Fd,Diaz-Rubio E,Tabernero JM,Schoffski P,Figer A,Brunet R,Grossmann J,Sobrero AF,Van Cutsem EJ

    更新日期:2005-07-01 00:00:00

  • Interval colorectal cancer after colonoscopy.

    abstract:BACKGROUND:As more patients are screened for colorectal cancer a small but significant number of interval cancers develop after colonoscopy for colorectal cancer screening. MATERIALS AND METHODS:We reviewed records of 75,314 adult patients who underwent colonoscopy for screening or diagnostic purposes between 1998 and...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章


    authors: Richter JM,Campbell EJ,Chung DC

    更新日期:2015-03-01 00:00:00

  • Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.

    abstract:INTRODUCTION:Bevacizumab improves outcome for patients with advanced colorectal cancer (CRC) when added to chemotherapy. The HORIZON I trial resulted in similar outcome with bevacizumab or cediranib, a small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor, as treatment of advanc...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,随机对照试验


    authors: Bar J,Spencer S,Morgan S,Brooks L,Cunningham D,Robertson J,Jürgensmeier JM,Goss GD

    更新日期:2014-03-01 00:00:00